A groundbreaking discovery reveals that a fat-burning protein called HSL (hormone-sensitive lipase) has been doing far more than scientists realized for decades. Researchers at the University of Toulouse found that HSL operates in two completely different ways inside fat cells: it releases stored fat when the body needs energy, but it also protects the health and function of fat cells from deep within the cell nucleus. This dual role could fundamentally change how doctors approach obesity treatment.

What Does This Discovery Mean for How We Understand Fat?

For over 60 years, scientists believed HSL worked primarily as the body's emergency fuel switch. When you fast or exercise, hormones like adrenaline trigger HSL to break down stored fat into fatty acids that other organs can use for energy. But researchers discovered something unexpected: HSL also operates inside the nucleus, the control center of fat cells where DNA is stored and genes are regulated.

The discovery solved a long-standing mystery in obesity research. Scientists had assumed that removing HSL would prevent fat breakdown and lead to obesity. Instead, people and mice with mutations in the HSL gene developed lipodystrophy, a rare condition where the body loses healthy fat tissue rather than gaining it. This contradiction puzzled researchers for years until they found HSL's hidden nuclear role.

"HSL has been known since the 1960s as a fat-mobilizing enzyme. But we now know that it also plays an essential role in the nucleus of adipocytes, where it helps maintain healthy adipose tissue," explained Dominique Langin, lead researcher at the Institute of Cardiovascular and Metabolic Diseases at the University of Toulouse.

Dominique Langin, Lead Researcher at the Institute of Cardiovascular and Metabolic Diseases, University of Toulouse

Why Is Fat Cell Health More Important Than Just Weight Loss?

The research reveals that obesity and lipodystrophy, though they seem opposite, actually share many of the same health complications. In obesity, fat tissue becomes enlarged and dysfunctional. In lipodystrophy, the body lacks enough properly functioning fat tissue. In both cases, fat cells fail to regulate energy normally, which can contribute to insulin resistance, type 2 diabetes, fatty liver disease, inflammation, and cardiovascular problems.

This overlap suggests something crucial: the quality and function of fat cells may be just as important as the amount of fat the body carries. Inside the nucleus, HSL appears to help regulate important cellular systems, including mitochondrial activity (the energy-producing structures in cells) and the extracellular matrix (the structural support system for tissues). Problems in either system have been linked to obesity, inflammation, and metabolic disease.

The amount of HSL inside the nucleus also changes based on the body's metabolic state. During fasting, adrenaline activates HSL and pushes it out of the nucleus so it can mobilize fat stores. In obese mice fed a high-fat diet, nuclear HSL levels increased, suggesting the protein's movement is controlled by signaling pathways involved in inflammation and tissue remodeling.

How Might This Change Future Obesity Treatments?

• Shift from Weight Elimination to Function Preservation: Many current obesity therapies focus mainly on reducing fat mass. The study suggests that preserving healthy fat tissue function could be equally important, potentially leading to more effective long-term outcomes.
• Understanding Why Some Treatments Succeed: The discovery may help researchers better understand why some obesity treatments work while others fail, by revealing which therapies actually maintain healthy fat cell function rather than just shrinking fat stores.
• Targeting Cellular Health Systems: Future treatments may focus on restoring the normal function of adipocytes and protecting the biological systems that keep fat tissue healthy, including mitochondrial activity and tissue structure, rather than simply trying to eliminate fat.

The findings, published in Cell Metabolism, arrived as obesity rates continue to rise worldwide. According to global estimates, billions of people are now overweight or obese, increasing the risk of diabetes, heart disease, stroke, sleep apnea, and some cancers. Researchers hope that understanding how proteins like HSL regulate fat cell health could eventually lead to more targeted therapies for metabolic disease.

Meanwhile, access to weight loss medications continues to expand. CVS Caremark, one of the country's largest pharmacy benefit managers, announced it will resume covering Eli Lilly's weight loss drug Zepbound starting October 1, 2026, after removing it from its formulary last year sparked significant patient backlash. Some patients with private insurance could pay as little as a $25 copay for the medication, which has a monthly list price of $1,086.

The decision to restore Zepbound coverage comes after patients reported being forced to switch to rival drug Wegovy from Novo Nordisk despite achieving better results on Zepbound. A class-action lawsuit challenging the original removal decision was filed in September and remains active. Lilly's newer weight loss pill, Foundayo, which was approved in April, will also be added to CVS Caremark's formulary starting immediately.

The convergence of these developments, from fundamental discoveries about how fat cells function to improved medication access, suggests the field of weight management is undergoing significant transformation. Rather than viewing obesity as simply a matter of calories consumed versus calories burned, researchers increasingly recognize that adipose tissue acts as a complex endocrine organ that communicates with the brain, liver, muscles, and immune system through hormones and signaling molecules. Dysfunctional fat tissue can disrupt the body far beyond weight gain alone.